Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Gamma distribution

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Gamma distribution. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-004216-70 Sponsor Protocol Number: BM17864 Start Date*: 2007-01-30
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A randomized, double-blind, parallel group, placebo-controlled (with open-label active comparator arm), dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of RO...
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000956-32 Sponsor Protocol Number: 20022012 Start Date*: 2012-06-28
    Sponsor Name:St. Antonius Ziekenhuis
    Full Title: Pharmacokinetics of intravenous acetaminophen and its metabolites in morbidly obese patients
    Medical condition: Morbid obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004655-21 Sponsor Protocol Number: KRN-001 Start Date*: 2014-06-23
    Sponsor Name:Kern Pharma S.L.
    Full Title: New Dosing Systems in Paediatrics. Application to the individualization of the dose of fentanyl in neonatal patients.
    Medical condition: Analgesia, sedation.
    Disease:
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004742-41 Sponsor Protocol Number: KRN-002 Start Date*: 2014-03-11
    Sponsor Name:Kern Pharma S.L.
    Full Title: New Dosing Systems in Paediatrics. Application to the individualization of the dose of fentanyl in patients between 1 month and 16 years of age.
    Medical condition: Analgesia, sedation.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002341-35 Sponsor Protocol Number: GA1103 Start Date*: 2011-07-21
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd
    Full Title: A randomised single dose two cohort study comparing the speed of raft formation assessed by gamma scintigraphy in healthy volunteers following administration of a single dose of Gaviscon® Strawberr...
    Medical condition: To measure the formation and retention of alginate rafts in healthy volunteers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002470-40 Sponsor Protocol Number: PROSORA Start Date*: 2017-11-16
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: Observational study of the effects of probenecid on the pharmacokinetics and pharmacodynamics of sorafenib (PROSORA-study)
    Medical condition: patients with unresectable hepatocellular cancer, advanced clear-cell renal cell carcinoma, locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-002616-16 Sponsor Protocol Number: NL49061.031.14 Start Date*: 2014-07-10
    Sponsor Name:NKI-AVL
    Full Title: Pilot for high-resolution SPECT imaging of breast cancer lumpectomy specimens for 3D identification and quantification of resection margins
    Medical condition: Patients with breast cancer, IDC (n=3) and DCIS (n=3) scheduled for a lumpectomy.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022726-33 Sponsor Protocol Number: 251001 Start Date*: 2011-03-24
    Sponsor Name:Baxter Innovations GmbH
    Full Title: BAX326 (recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level 1- 2%) Hemo...
    Medical condition: Previously treated patients (PTPs) with severe (FIX level < 1%) or moderately severe (FIX level 1- 2%) hemophilia B.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Completed) CZ (Completed) GB (Completed) DE (Prematurely Ended) SE (Completed) PL (Completed) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003483-59 Sponsor Protocol Number: CVAL489A2429 Start Date*: 2006-12-18
    Sponsor Name:VU University Medical Centre
    Full Title: PRESERVE TRIAL: Pancreatic beta-cell dysfunction REStorEd by Rosiglitazone and Valsartan Effects; A 52-week randomized controlled factorial study in subjects with impaired fasting glucose and/or im...
    Medical condition: subjects with impaired fasting glucose (IFG; blood glucose > or = 5.6 and < 7 mmol/l) and/or impaired glucose tolerance (IGT; 2-h post-load glucose 7.8-11.1 mmol/l).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10018429 Glucose tolerance impaired LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017296-17 Sponsor Protocol Number: TESEC-03 Start Date*: 2011-04-04
    Sponsor Name:Statens Serum Institut
    Full Title: A phase IIa specificity trial of the diagnostic agent C-Tb, when given intradermally by the Mantoux technique to healthy volunteers previously vaccinated with BCG
    Medical condition: The intended indication for the product is to be a diagnostic tool to detect infection with M.tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    10 10044755 tuberculosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000413-39 Sponsor Protocol Number: 251002 Start Date*: 2011-10-06
    Sponsor Name:Baxter Innovations GmbH
    Full Title: BAX 326 (recombinant factor IX): A Phase 3 Prospective, Multicenter Study Evaluating Efficacy and Safety in Previously Treated Patients With Severe (FIX level < 1%) or Moderately Severe (FIX level ...
    Medical condition: Previously treated patients with severe (FIX level < 1%) or moderately severe (FIX level ≤ 2%) hemophilia B undergoing surgical or other invasive procedures
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) SE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002763-25 Sponsor Protocol Number: NT2013/Orv/Prot001 Start Date*: 2013-10-11
    Sponsor Name:NeRRe Therapeutics Ltd
    Full Title: A randomised, double-blind, placebo-controlled study to evaluate the efficacy of two different dose levels of orvepitant (10 and 30 mg) compared with placebo on EGFRi-induced intense pruritus in on...
    Medical condition: Intense pruritus, in oncology subjects, induced by EGFRi
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004858 10023084 Itching LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000809-23 Sponsor Protocol Number: AB12003 Start Date*: 2014-10-10
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo i...
    Medical condition: metastatic Castrate Resistant Prostate Cancer (mCRPC).
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Restarted) SK (Prohibited by CA) GR (Completed) CZ (Completed) GB (Temporarily Halted) IT (Suspended by CA)
    Trial results: (No results available)
    EudraCT Number: 2021-006766-21 Sponsor Protocol Number: MINI-SPIOMET Start Date*: 2022-09-02
    Sponsor Name:Hospital de Girona Dr. Josep Trueta
    Full Title: Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study.
    Medical condition: Girls with advanced puberty and accelerated bone maturation. Polycystic Ovary Syndrome (PCOS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10014054 Early puberty LLT
    Population Age: Children, Under 18 Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018982-43 Sponsor Protocol Number: AB08025 Start Date*: 2010-06-18
    Sponsor Name:AB SCIENCE
    Full Title: A prospective, multicenter, open-label, uncontrolled, two-parallel group, phase 1/2 study to evaluate safety and efficacy of masitinib at 9 mg/kg/day in monotherapy and in combination with dacarbaz...
    Medical condition: Mélanome métastasé ou non-opérable stade 3 ou stade 4, ne portant pas de mutation dans le domaine juxta-membranaire de c-kit
    Disease: Version SOC Term Classification Code Term Level
    12.1 10025670 Malignant melanoma stage III LLT
    12.1 10025671 Malignant melanoma stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005679-18 Sponsor Protocol Number: GMX04 Start Date*: 2011-12-07
    Sponsor Name:Bio Products Laboratory Limited
    Full Title: A Phase IV, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases (PID) in Children and Adolescents
    Medical condition: Primary immunodeficiency diseases
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: Removed from public view
    EudraCT Number: 2019-004602-94 Sponsor Protocol Number: BIO101_CL04 Start Date*: 2020-03-27
    Sponsor Name:Biophytis
    Full Title: A 3-part, Randomized, Double Blind, Adaptive Seamless Phase 1-3 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of BIO101 in Non-Ambulatory Patients with a Geneticall...
    Medical condition: Duchenne Muscular Dystrophy regardless the genotype
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004287-30 Sponsor Protocol Number: LAL-CL06 Start Date*: 2014-06-19
    Sponsor Name:Alexion Pharmaceuticals inc
    Full Title: A Multicenter, Open-Label Study of Sebelipase Alfa in Patients with Lysosomal Acid Lipase Deficiency
    Medical condition: Lysosomal Acid Lipase Deficiency (LALD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10024579 Lysosomal storage disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed) ES (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) BE (Completed) HR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004793-26 Sponsor Protocol Number: HPN217-3001 Start Date*: 2020-06-24
    Sponsor Name:Harpoon Therapeutics, Inc.
    Full Title: A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma
    Medical condition: Relapsed/Refractory Multiple Myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003255-54 Sponsor Protocol Number: RGB-03-104 Start Date*: 2015-01-21
    Sponsor Name:Gedeon Richter Plc
    Full Title: A Double-blind, Randomised, Comparative Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Evaluation of RGB-03 and MabThera® Combined with Methotrexate in Rheumatoid Arthritis Patients
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jul 05 12:09:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA